(EVH) Evolent Health - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 251m USD | Total Return: -76.1% in 12m
Care Management, Health Platform, Admin Services, AI Tools
Total Rating 20
Safety 39
Buy Signal -1.06
Health Information Services
Industry Rotation: -0.9
Industry Rotation: -0.9
Market Cap:
251M
Avg Turnover: 7.31M USD
Avg Turnover: 7.31M USD
ATR:
9.12%
Peers RS (IBD): 3.1
Peers RS (IBD): 3.1
Risk 5d forecast
Volatility82.5%
Rel. Tail Risk-21.7%
Reward TTM
Sharpe Ratio-1.78
Alpha-98.97
Character TTM
Beta1.283
Beta Downside1.077
Drawdowns 3y
Max DD94.05%
CAGR/Max DD-0.63
EPS (Earnings per Share)
EPS CAGR: -15.84%
EPS Trend: -58.6%
EPS Trend: -58.6%
Last SUE: -0.42
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 12.93%
Rev. Trend: 63.1%
Rev. Trend: 63.1%
Last SUE: 0.02
Qual. Beats: 0
Qual. Beats: 0
Warnings
volatile
Tailwinds
No distinct edge detected
Description: EVH Evolent Health
Evolent Health, Inc. (NYSE: EVH) is a Virginia-based healthcare technology company specializing in specialty care management for high-cost clinical areas, including oncology, cardiology, and musculoskeletal health. The firm operates a value-based care model, which aligns financial incentives with patient outcomes rather than the volume of services provided. Its core business infrastructure supports health plan administration and risk management for integrated delivery networks and independent health plans.
The company utilizes its proprietary Identifi platform to aggregate clinical data and manage care workflows, alongside AI-driven software such as Machinify Auth to streamline authorizations. In the Health Care Technology sector, firms like Evolent are increasingly focused on reducing administrative waste, which is estimated to account for approximately 15% to 30% of total healthcare spending in the United States. Prospective investors may find it useful to review the companys valuation metrics on ValueRay to better understand its market position. Evolent’s suite of services includes pharmacy benefits management and holistic cost-of-care analytics designed to improve provider performance and patient engagement.
- Growth in value-based care contracts expands revenue streams
- AI-powered prior authorization tools enhance operational efficiency
- Regulatory changes in healthcare impact service demand
- Expansion into new specialty care markets drives growth
- Health plan administrative services provide recurring revenue
Piotroski VR‑10 (Strict)
1.5
| Net Income: -534.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 0.49 > 1.0 |
| NWC/Revenue: 6.46% < 20% (prev -4.24%; Δ 10.70% < -1%) |
| CFO/TA 0.02 > 3% & CFO 38.8m > Net Income -534.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.2m) vs 12m ago -0.72% < -2% |
| Gross Margin: 15.09% > 18% (prev 0.14%; Δ 1.49k% > 0.5%) |
| Asset Turnover: 84.45% > 50% (prev 100.4%; Δ -15.96% > 0%) |
| Interest Coverage Ratio: -8.30 > 6 (EBITDA TTM -361.3m / Interest Expense TTM 57.5m) |
Altman Z''
-4.21
| A: 0.06 (Total Current Assets 506.4m - Total Current Liabilities 385.3m) / Total Assets 1.90b |
| B: -0.69 (Retained Earnings -1.32b / Total Assets 1.90b) |
| C: -0.21 (EBIT TTM -477.2m / Avg Total Assets 2.22b) |
| D: -0.89 (Book Value of Equity -1.32b / Total Liabilities 1.48b) |
| Altman-Z'' Score: -4.21 = D |
Beneish M
-3.55
| DSRI: 1.06 (Receivables 323.4m/414.7m, Revenue 1.88b/2.55b) |
| GMI: 0.95 (GM 15.09% / 14.38%) |
| AQI: 0.94 (AQ_t 0.69 / AQ_t-1 0.73) |
| SGI: 0.73 (Revenue 1.88b / 2.55b) |
| TATA: -0.30 (NI -534.5m - CFO 38.8m) / TA 1.90b) |
| Beneish M-Score: -3.55 (Cap -4..+1) = AAA |
What is the price of EVH shares?
As of April 06, 2026, the stock is trading at USD 2.25 with a total of 2,490,100 shares traded.
Over the past week, the price has changed by +3.69%, over one month by -33.82%, over three months by -43.04% and over the past year by -76.06%.
Over the past week, the price has changed by +3.69%, over one month by -33.82%, over three months by -43.04% and over the past year by -76.06%.
Is EVH a buy, sell or hold?
Evolent Health has received a consensus analysts rating of 4.57.
Therefore, it is recommended to buy EVH.
- StrongBuy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EVH price?
| Wallstreet Target Price | 5.2 | 130.2% |
| Analysts Target Price | 5.2 | 130.2% |
EVH Fundamental Data Overview
as of 04 April 2026
P/E Forward = 12.3305 P/S = 0.1339
P/B = 0.5969
P/EG = -1.37
Revenue TTM = 1.88b USD
EBIT TTM = -477.2m USD
EBITDA TTM = -361.3m USD
Long Term Debt = 970.5m USD (from longTermDebt, last quarter)
Short Term Debt = 15.3m USD (from shortTermDebt, last quarter)
Debt = 989.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 837.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (251.2m + Debt 989.7m - CCE 151.9m)
Interest Coverage Ratio = -8.30 (Ebit TTM -477.2m / Interest Expense TTM 57.5m)
EV/FCF = 229.0x (Enterprise Value 1.09b / FCF TTM 4.75m)
FCF Yield = 0.44% (FCF TTM 4.75m / Enterprise Value 1.09b)
FCF Margin = 0.25% (FCF TTM 4.75m / Revenue TTM 1.88b)
Net Margin = -28.49% (Net Income TTM -534.5m / Revenue TTM 1.88b)
Gross Margin = 15.09% ((Revenue TTM 1.88b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = -4.18% (prev 20.81%)
Tobins Q-Ratio = 0.57 (Enterprise Value 1.09b / Total Assets 1.90b)
Interest Expense / Debt = 1.92% (Interest Expense 19.0m / Debt 989.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -377.0m (EBIT -477.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.31 (Total Current Assets 506.4m / Total Current Liabilities 385.3m)
Debt / Equity = 2.38 (Debt 989.7m / totalStockholderEquity, last quarter 415.2m)
Debt / EBITDA = -2.32 (negative EBITDA) (Net Debt 837.8m / EBITDA -361.3m)
Debt / FCF = 176.2 (Net Debt 837.8m / FCF TTM 4.75m)
Total Stockholder Equity = 772.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.06% (Net Income -534.5m / Total Assets 1.90b)
RoE = -69.22% (Net Income TTM -534.5m / Total Stockholder Equity 772.2m)
RoCE = -27.38% (EBIT -477.2m / Capital Employed (Equity 772.2m + L.T.Debt 970.5m))
RoIC = -22.31% (negative operating profit) (NOPAT -377.0m / Invested Capital 1.69b)
WACC = 3.34% (E(251.2m)/V(1.24b) * Re(10.50%) + D(989.7m)/V(1.24b) * Rd(1.92%) * (1-Tc(0.21)))
Discount Rate = 10.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.27%
[DCF] Terminal Value 80.82% ; FCFF base≈4.75m ; Y1≈3.12m ; Y5≈1.43m
[DCF] Fair Price = N/A (negative equity: EV 45.3m - Net Debt 837.8m = -792.5m; debt exceeds intrinsic value)
EPS Correlation: -58.59 | EPS CAGR: -15.84% | SUE: -0.42 | # QB: 0
Revenue Correlation: 63.06 | Revenue CAGR: 12.93% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.02 | Chg7d=-0.074 | Chg30d=-0.074 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-12-31): EPS=0.17 | Chg7d=-0.130 | Chg30d=-0.130 | Revisions Net=-5 | Growth EPS=+90.7% | Growth Revenue=+32.9%
EPS next Year (2027-12-31): EPS=0.44 | Chg7d=-0.067 | Chg30d=-0.067 | Revisions Net=-5 | Growth EPS=+157.4% | Growth Revenue=+15.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
External Resources